No label defined (Q30832)
Jump to navigation
Jump to search
No description defined
- Gender-affirming hormone therapy for transgender and gender-diverse adults in Australia.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
Gender-affirming hormone therapy (GAHT) is used by many transgender and gender-diverse adults to align physical characteristics with their gender identity, reduce gender incongruence and improve psychological functioning. (English)
© 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. (English)
2024
This narrative review provides an overview of the initiation and monitoring of GAHT in an Australian context. (English)
© 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. (English)
2024
Trans individuals treated with testosterone typically receive standard testosterone doses and formulations recommended for cisgender men, whereas those receiving estradiol GAHT are typically treated with estradiol in combination with an anti-androgen in those without orchidectomy. (English)
© 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. (English)
2024
Proactive monitoring and mitigation of cardiovascular risk factors is pertinent in all transgender and gender-diverse adults and bone health is an important consideration in those using estradiol GAHT. (English)
© 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. (English)
2024
Brendan J (English)
Nolan (English)
BJ
Ada S (English)
Cheung (English)
AS
6 September 2024
6 September 2024